Published using Google Docs
Minutia-CIRM Press Release_DRAFT_2.15.23.docx
Updated automatically every 5 minutes


Media Contacts:

Minutia receives $1,198,550 grant from California Institute for Regenerative Medicine

Berkeley, CA August, 2022 – Minutia, Inc., an innovative Oakland and Berkeley-based life sciences startup, announced today the award of a $1,198,550.00 grant from the California Institute for Regenerative Medicine (CIRM) to help advance Minutia’s mission to create a functional cure for Type 1 diabetes. The grant will directly fund Minutia’s ongoing work with subcutaneous transplants of insulin-producing cells. Specifically, the funds will support further development of technology that allows an immune attack to be measured after transplantation, allowing for timely interventions by surgical teams to save graft function and extend the duration of insulin independence.

“We are honored to begin this collaboration with CIRM,” stated Katy Digovich, Minutia’s co-founder and CEO. “As someone who has been living with Type 1 diabetes for over 25 years, I look to them for cutting-edge support for gene therapies for currently incurable diseases or disorders.

Housed in the Bakar BioEnginuity Hub at the University of California, the company began operations in January 2021, and has already demonstrated the efficacy of their robust insulin-producing cells and their intracellular sensors in animal models. In addition, Minutia has a proof of concept of their less-invasive transplant protocol in a PI-led phase 1/2 clinical trial.

Together with previous grants from the NIH and the JDRF, CIRM’s award positions Minutia as a key player in the development of Type 1 diabetes therapeutics and potential cures.


Minutia is a preclinical biotechnology company developing a unique approach to transplants of insulin-producing cells designed to lead to a cure for diabetes. Based in Oakland and Berkeley, CA, Minutia was launched in 2021 as a commercial spinout to research conducted at Duke University and UCSF.